AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New trial aims to snuff out hidden leukemia before it returns
Disease control OngoingThis early-phase trial tests whether a combination of two drugs, MBG-453 and azacitidine, can eliminate leftover cancer cells in people with acute myeloid leukemia (AML). The goal is to prevent relapse by treating the disease when it is still at a very low level. Only 3 participa…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New chemo cocktail aims to boost survival in elderly leukemia patients
Disease control OngoingThis phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regim…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo tackles relapsed blood cancers after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in 55 adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that returned after a stem cell transplant. The goal is to find the best dose and see if the treatment…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo targets tough leukemia in early trial
Disease control OngoingThis study tests a new combination of two drugs (gemtuzumab ozogamicin and gilteritinib) for adults with a specific genetic form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial aims to see if the combination is safe and helps control th…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC